Compare CDZI & DRUG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CDZI | DRUG |
|---|---|---|
| Founded | 1983 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Water Supply | Pharmaceuticals and Biotechnology |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 444.6M | 364.8M |
| IPO Year | N/A | N/A |
| Metric | CDZI | DRUG |
|---|---|---|
| Price | $5.79 | $84.00 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 8 |
| Target Price | N/A | ★ $89.00 |
| AVG Volume (30 Days) | ★ 602.2K | 178.8K |
| Earning Date | 11-13-2025 | 02-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $15,979,000.00 | N/A |
| Revenue This Year | $58.18 | N/A |
| Revenue Next Year | $32.89 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 188.33 | N/A |
| 52 Week Low | $2.13 | $23.18 |
| 52 Week High | $6.49 | $97.75 |
| Indicator | CDZI | DRUG |
|---|---|---|
| Relative Strength Index (RSI) | 56.38 | 57.71 |
| Support Level | $5.36 | $75.11 |
| Resistance Level | $5.95 | $89.71 |
| Average True Range (ATR) | 0.29 | 7.19 |
| MACD | 0.00 | -1.33 |
| Stochastic Oscillator | 80.04 | 39.27 |
Cadiz Inc is a water solutions provider, dedicated to delivering clean, reliable, and affordable water for people. It provides water solutions with a combination of land, water, pipeline, and water filtration assets located in Southern California between key water systems serving population centers in the Southwestern United States. The company operates in two reportable segments; Land and Water Resources segment, which derives key revenue, and comprises all activities regarding its properties in the eastern Mojave Desert, pre-revenue development of the Mojave Groundwater Bank (supply, storage, and conveyance), and agricultural operations; and the Water Filtration Technology segment, which provides water filtration solutions for impaired or contaminated groundwater sources.
Bright Minds Biosciences Inc is focused on developing novel transformative treatments for neuropsychiatric disorders, epilepsy, and pain. The company has a portfolio of next-generation serotonin agonists designed to target neurocircuit abnormalities that are responsible for difficult to treat disorders such as resistant epilepsy, treatment resistant depression, PTSD, and pain. The company's drugs have been designed to potentially retain the powerful therapeutic aspects of psychedelic and other serotonergic compounds, while minimizing the side effects, thereby creating superior drugs to first-generation compounds, such as psilocybin.